Chr amplification(1)(q21)

News alerts, weekly reports and conference planners

Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	lenalidomide + APG-2575 Sensitive: D – Preclinical lenalidomide + APG-2575 Sensitive : D	lenalidomide + APG-2575 Sensitive: D – Preclinical lenalidomide + APG-2575 Sensitive : D

Associations